IL6ST-DT: A Protein Implicated in Disease (G441072)

Target Name: IL6ST-DT

NCBI ID: G441072

IL6ST-DT

Other Name(s): IL6ST divergent transcript

IL6ST-DT: A Protein Implicated in Disease

IL6ST-DT, also known as interleukin-6 (IL-6) signaling transducer-T, is a protein that is expressed in various tissues throughout the body, including immune cells, neurons, and epithelial cells. It is a key regulator of the immune response and has been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

IL6ST-DT has been shown to play a crucial role in the regulation of immune cell function and has been linked to the development and progression of a number of diseases. For example, high levels of IL-6 have been observed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, IL6 has been implicated in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

In addition to its role in disease, IL6ST-DT has also been shown to have potential as a drug target or biomarker. The ability of IL6ST-DT to regulate immune cell function and its association with a number of diseases make it an attractive target for drug development.

One approach to targeting IL6ST-DT is to use small molecules that can inhibit its activity. This is because the activity of IL6ST-DT is tightly regulated by a number of intracellular signaling pathways, including the TGF-β pathway. By inhibiting the activity of IL6ST-DT, researchers can reduce the production of immune cells and potentially slow the progression of diseases associated with high levels of IL-6.

Another approach to targeting IL6ST-DT is to use antibodies that can specifically recognize and target the protein. This approach is based on the idea that by binding to IL6ST-DT, antibodies can tag the protein and cause it to be degraded by the body's immune system. This can lead to a decrease in the levels of IL6ST-DT and potentially slow the progression of diseases associated with high levels of IL-6.

In addition to these approaches, researchers are also exploring the use of IL6ST-DT as a biomarker to diagnose and monitor diseases associated with high levels of IL-6. For example, researchers have shown that the levels of IL6ST-DT are significantly increased in the blood of individuals with rheumatoid arthritis, a type of autoimmune disorder that is characterized by inflammation and joint damage. By using IL6ST-DT as a biomarker, researchers can monitor the progression of rheumatoid arthritis and track the effectiveness of different treatments.

IL6ST-DT is also a potential target for cancer because it has been shown to promote the growth and survival of cancer cells. By inhibiting the activity of IL6ST-DT, researchers can potentially slow the growth of cancer cells and reduce their ability to spread and cause new infections.

In conclusion, IL6ST-DT is a protein that has been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Its activity as a regulator of immune cell function and its potential as a drug target or biomarker make it an attractive target for research and development. As research continues to progress, it will be interesting to see what new insights and findings emerge about the role of IL6ST-DT in disease.

Protein Name: IL6ST Divergent Transcript

The "IL6ST-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL6ST-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets